| Literature DB >> 28876467 |
Eugenio Ventimiglia1,2, Yasin Folkvaljon2, Stefan Carlsson3, Ola Bratt4,5, Francesco Montorsi1, Daniela Volz3, Olof Akre3, Eva Johansson2, Pär Stattin2,6.
Abstract
OBJECTIVES: To assess the use of post radical prostatectomy (RP) urinary incontinence (PPI) surgery and to investigate factors related to its use.Entities:
Keywords: PROM; artificial urinary sphincter; population based; post radical prostatectomy urinary incontinence
Mesh:
Year: 2017 PMID: 28876467 PMCID: PMC5873254 DOI: 10.1002/jso.24816
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454
Baseline characteristics for men diagnosed with prostate cancer from 1998 to 2012 in Prostate Cancer data Base Sweden (PCBaSe) 3.0 treated with radical prostatectomy (RP) stratified by receipt of post prostatectomy urinary incontinence (PPI) correction surgery
| PPI surgery | All | |
|---|---|---|
|
|
| |
| Age at RP (years) | ||
| Median (IQR) | 64 (60‐68) | 63 (59‐67) |
| <60 | 166 (21) | 7410 (28) |
| 60‐64 | 256 (33) | 8267 (31) |
| 65‐69 | 240 (31) | 7814 (30) |
| ≥70 | 120 (15) | 2789 (11) |
| Aggregated risk category | ||
| Favorable‐risk | 629 (80) | 22 175 (84) |
| Aggressive disease | 141 (18) | 3745 (14) |
| Missing | 12 (2) | 360 (1) |
| Year of RP | ||
| 1998‐2000 | 56 (7) | 1727 (7) |
| 2001‐2003 | 120 (15) | 3474 (13) |
| 2004‐2006 | 240 (31) | 6794 (26) |
| 2007‐2009 | 235 (30) | 6762 (26) |
| 2010‐2012 | 131 (17) | 7523 (29) |
| Year of PPI correction surgery | ||
| 2000‐2002 | 27 (3) | 27 (3) |
| 2003‐2005 | 80 (10) | 80 (10) |
| 2006‐2008 | 171 (22) | 171 (22) |
| 2009‐2011 | 260 (33) | 260 (33) |
| 2012‐2014 | 244 (31) | 244 (31) |
| Multiple PPI correction surgeries | ||
| No | 586 (75) | |
| Yes | 196 (25) | |
| Time to PPI correction surgery (years) | ||
| Median (IQR) | 2.8 (1.8‐4.3) | |
| <1 year | 29 (4) | |
| 1‐2 years | 204 (26) | |
| 2‐3 years | 202 (26) | |
| 3‐4 years | 118 (15) | |
| >4 years | 229 (29) | |
| Charlson comorbidity index | ||
| 0 | 672 (86) | 23 319 (89) |
| 1 | 74 (9) | 1804 (7) |
| 2+ | 36 (5) | 1157 (4) |
| Marital status | ||
| Married | 593 (76) | 19 362 (74) |
| Not married | 189 (24) | 6904 (26) |
| Missing | 0 (0) | 14 (0) |
| Education level | ||
| High | 212 (27) | 8044 (31) |
| Intermediate | 329 (42) | 10 784 (41) |
| Low | 238 (30) | 7333 (28) |
| Missing | 3 (0) | 119 (0) |
| RP center volume | ||
| <50 | 358 (46) | 12 402 (47) |
| 50‐99 | 217 (28) | 6619 (25) |
| 100+ | 207 (26) | 7259 (28) |
| PPI correction surgery center volume | ||
| <10 | 684 (87) | 23 165 (88) |
| 10‐15 | 37 (5) | 1156 (4) |
| >15 | 61 (8) | 1959 (7) |
IQR, interquartile range.
PPI correction surgery defined by KDK00: diagnostic code for urinary incontinence surgery of the NOMESCO Classification of Surgical Procedures (NCSP), version 1.16.
Prostate cancer risk categories according to modified NCCN categorisation: Low‐risk = T1‐2, Prostate‐specific antigen (PSA) <10 ng/mL and Gleason score (GS) ≤6; Intermediate‐risk = T1‐2, PSA <20 ng/mL and PSA 10‐19.9 ng/mL or GS 7; High‐risk = T1 2, PSA <50 ng/mL with GS 8 10 or PSA 20‐49.9 ng/mL; Locally advanced = T3 and PSA <50 ng/mL; Regionally metastatic = PSA <100 ng/mL with T4 or PSA 50‐99.9 ng/mL or N1; Distant metastases = PSA ≥100 ng/mL or M1. Aggregated risk categories: favorable‐risk included low‐risk and intermediate‐risk cancer; aggressive disease included high‐risk, locally advanced, regionally metastatic, and distant metastases.
Education level is low: <10 years of education; middle: 10‐12 years; high: >12 years.
RP center volume: number of RPs performed at a center in the year before the RP in this study.
PPI surgery center volume the number of PPI surgeries performed in the year before the study RP.
Figure 1Numbers of post prostatectomy urinary incontinence (PPI) correction surgery per year and PPI correction surgery per 1000 radical prostatectomies performed during 2 preceding years. RP: radical prostatectomy
Hazard ratios (HR) and 95% confidence intervals (CI) for post prostatectomy urinary incontinence (PPI) correction surgery
| Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
|
| HR | 95%CI | HR | 95%CI | |
| Age at RP (years) | |||||
| <60 | 7299 (165) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| 60‐64 | 8128 (254) | 1.41 | 1.16‐1.72 | 1.37 | 1.13‐1.67 |
| 65‐69 | 7674 (233) | 1.43 | 1.17‐1.75 | 1.37 | 1.12‐1.67 |
| ≥70 | 2700 (115) | 2.13 | 1.68‐2.70 | 1.96 | 1.54‐2.50 |
| Charlson comorbidity index | |||||
| 0 | 22 954 (658) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| 1 | 1792 (73) | 1.46 | 1.15‐1.86 | 1.36 | 1.06‐1.73 |
| 2+ | 1055 (36) | 1.30 | 0.93‐1.82 | 1.19 | 0.85‐1.67 |
| Aggregated risk category | |||||
| Favorable‐risk | 22 080 (627) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| Aggressive disease | 3721 (140) | 1.39 | 1.15‐1.66 | 1.29 | 1.07‐1.55 |
| Post‐operative radiotherapy | |||||
| No | 23 750 (697) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| Yes | 2051 (70) | 1.19 | 0.93‐1.52 | 1.08 | 0.84‐1.39 |
| RP center volume | |||||
| <50 | 12 199 (380) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| 50‐99 | 6529 (207) | 1.13 | 0.95‐1.33 | 1.07 | 0.90‐1.27 |
| >100 | 7073 (180) | 0.91 | 0.76‐1.08 | 0.81 | 0.66‐0.99 |
| PPI correction surgery center volume | |||||
| <10 | 22 796 (675) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| 10‐15 | 1093 (34) | 1.18 | 0.83‐1.66 | 1.42 | 0.99‐2.05 |
| >15 | 1912 (58) | 1.42 | 1.08‐1.86 | 1.71 | 1.27‐2.30 |
| Education level | |||||
| Low | 7240 (237) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| Intermediate | 10 637 (322) | 0.95 | 0.80‐1.12 | 0.99 | 0.84‐1.17 |
| High | 7924 (208) | 0.83 | 0.69‐0.99 | 0.86 | 0.71‐1.04 |
| Marital status | |||||
| Married | 19 044 (581) | 1.00 | (Ref.) | 1.00 | (Ref.) |
| Not married | 6757 (186) | 0.93 | 0.79‐1.10 | 0.95 | 0.81‐1.12 |
PPI correction surgery defined by KDK00: diagnostic code for urinary incontinence surgery of the NOMESCO Classification of Surgical Procedures (NCSP), version 1.16.
Prostate cancer risk categories according to modified NCCN categorisation: Low‐risk = T1‐2, Prostate‐specific antigen (PSA) <10 ng/mL and Gleason score (GS) ≤6; Intermediate‐risk = T1‐2, PSA <20 ng/mL and PSA 10‐19.9 ng/mL or GS 7; High‐risk = T1 2, PSA <50 ng/mL with GS 8 10 or PSA 20‐49.9 ng/mL; Locally advanced = T3 and PSA <50 ng/mL; Regionally metastatic = PSA <100 ng/mL with T4 or PSA 50‐99.9 ng/mL or N1; Distant metastases = PSA ≥100 ng/mL or M1.
RP center volume: number of RPs performed at a center in the year before the RP in this study.
PPI correction surgery center volume the number of PPI surgeries performed in the year before the study RP.
Educational level is low: <10 years of education; middle: 10‐12 years; high: >12 years. Aggregated risk categories: favorable‐risk included low‐risk and intermediate‐risk cancer; aggressive disease included high‐risk, locally advanced, regionally metastatic, and distant metastases.
Figure 2Proportion of men who underwent a post prostatectomy urinary incontinence (PPI) correction surgery per county of residence. A (since 2011), B, N, O, P, R, and U are counties with a university hospital
Figure 3Multivariable adjusted hazard rations (HRs) and 95% confidence intervals (Cis) for receipt of post prostatectomy urinary incontinence correction surgery according to the county of residence. Model adjusted for: age at RP, CCI, education, marital status, RP center volume, PPI surgery centere volume, risk category, post‐operative radiotherapy. At risk: number of RPs. Events: number of PPI correction surgery. PPI correction surgery = KDK00, diagnostic code for urinary incontinence surgery of the NOMESCO Classification of Surgical Procedures (NCSP), version 1.16. Educational level is low: <10 years of education; middle: 10‐12 years; high: >12 years. Favorable‐risk includes low‐risk and intermediate‐risk cancer. Aggressive disease includes high‐risk, locally advanced, regionally metastatic, and distant metastases. Prostate cancer risk categories according to modified NCCN categorisation: Low‐risk = T1‐2, Prostate‐specific antigen (PSA) <10 ng/mL and Gleason score (GS) ≤6; Intermediate‐risk = T1‐2, PSA <20 ng/mL and PSA 10‐19.9 ng/mL or GS 7; High‐risk = T1 2, PSA <50 ng/mL with GS 8 10 or PSA 20‐49.9 ng/mL; Locally advanced = T3 and PSA <50 ng/mL; Regionally metastatic = PSA <100 ng/mL with T4 or PSA 50‐99.9 ng/mL or N1; Distant metastases = PSA ≥100 ng/mL or M1. RP center volume: number of RPs performed at a center in the year before the RP in this study. PPI correction surgery center volume the number of PPI correction surgeries performed in the year before the study RP. **County with a university hospital